THIS IS A BRAND MEDICATION
THERAPEUTIC INDICATIONS: Anticonvulsant.
Epilepsy: DEPAKENE and cover the whole therapeutic spectrum of epileptic seizures in adults and children 10 years of age and older. In children under 10 years of age should be cautious of high risk of hepatotoxicity and hyperammonemic encephalopathy should be altered in the urea cycle.
DEPAKENE are indicated in patients with simple and complex partial seizures that occur in isolation or associated with another type of crisis, as monotherapy or added.
DEPAKENE and are indicated as monotherapy or therapy for the treatment of generalized seizures, absence seizures as simple or complex, tonic, clonic, myoclonic and grand mal seizures. In addition to epileptic syndromes.
Migraine:DEPAKENE Tablets is indicated for the prophylaxis of migraine headaches with aura or without aura, and to reduce the number of episodes or the severity of the crisis.
Mood Disorder: It is a heterogeneous group of diseases, typically recurrent, which includes unipolar disorder (depression) and bipolar (manic-depressive). It consists of mood disorders with infiltrative nature, which are accompanied by vegetative symptoms and psychomotor dysfunction.
DEPAKENE are indicated in the treatment of bipolar disorder in acute manic episode and mixed episodes associated with bipolar disorder, with or without psychotic features.
In the mood disorder is Inlcudes bipolar spectrum disorder, within which is the manic episode, which is an abnormal state of mind which is characterized by a state of persistently elevated mood, expansive and irritable. Also, mixed episode is characterized by gathering the diagnostic criteria for a manic episode and major depressive episode.
CONTRAINDICATIONS: Valproate semisodium or other valproate should not be administered to patients with liver disease or significant hepatic dysfunction. Is contraindicated in patients with known hypersensitivity to the drug, and / or changes in the urea cycle.
The concentration of valproate in the cerebrospinal fluid approaches the free concentration in plasma (about 10% of the total concentration). Therefore, patients taking enzyme-inducing antiepileptic drugs (carbamazepine, phenytoin and phenobarbital) should be monitored, and that will clear valproate quickly. Because of this, monitoring of antiepileptic concentrations should be intensified whenever concomitant antiepileptics increase or withdrawn.
The relationship between plasma concentration and clinical response is not well documented. One contributing factor is the nonlinear concentration-dependent protein binding of valproate, which affects drug clearance.
Liver disease impairs the ability to eliminate valproate. The clearance of free valproate in renal patients has been reported is slightly decreased, although it seems that there is no need to adjust the dose of valproate.
The therapeutic range in epilepsy is commonly considered 50 to 100 mg / ml of total valproate, although some patients can be controlled with lower or higher plasma concentrations. In controlled clinical research with placebo in acute mania patients had clinical response with plasma concentrations between 50 and 135 mg / ml.
Caution should be exercised when administering valproate DEPAKENE or any other patients with a history of liver disease, patients with severe epilepsy accompanied by mental retardation and those with organic brain disease, since there have been changes in liver function, including failure with fatal results in some patients receiving valproic acid. This has occurred during the first six months of treatment. Severe or fatal hepatotoxicity may be preceded by nonspecific symptoms such as loss of seizure control, malaise, weakness, lethargy, facial edema, anorexia and vomiting. In patients with epilepsy may occur a loss of seizure control. It should be tested for liver function before starting treatment and at frequent intervals thereafter, especially during the first six months.
However, should not rely entirely on the functional tests (blood chemistry), since they may not be abnormal in all cases, therefore, be considered the results of a thorough medical examination, carried out periodically.
Caution must be used when administering valproate semisodium patients with a history of liver disease with multiple anticonvulsants, children with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation and organic brain disease.
Experience has shown that children under two years are at greater risk of developing fatal hepatotoxicity, its use at this age should be done with extreme caution and as a single drug. The benefit of seizure control should be calculated against the risk. In older patients, the incidence of fatal hepatotoxicity decreases.
In the pediatric population is only recommended for children 10 years of age and older.
The drug should be discontinued immediately in the presence of liver dysfunction. In some cases, hepatic dysfunction has progressed despite discontinuation of the drug.
The frequency of adverse effects (particularly elevated liver enzymes and thrombocytopenia) may be dependent on the dose. The benefit of treatment to improve seizure control, which accompany the use of higher doses should be weighed against the possibility of higher incidence of adverse effects.
DOSAGE AND ADMINISTRATION: Depakene (valproic acid) is administered orally. The recommended starting dose in both children and adults is 15 mg / kg / day until seizure controlor side-effects that prevent further increases. The maximum recommended dose is 60 mg / kg/ day in divided doses. If the total dose is greater than 250 mg should be administered alsofractionated.
Initial dose: 15 mg / kg / day.
Dose adjustment: 5 to 10 mg / kg / day.
Maximum dose: 60 mg / kg / day ..
Medication name: Depakene
Comparable patent medicine: Depakene
Active ingredient: Valproic Acid
Concentration: 250 mg
Extended-release tablets: No
Lab: Abbott Laboratories de Mexico, SA de CV
box 60 tab
Made in: Mexico